MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • MDS Virtual Congress 2021

    Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

    K. Biglan, L. Munsie, K. Svensson, P. Ardayfio, M. Pugh, J. Sims, M. Brys (Indianapolis, USA)

    Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia

    K. Klos, J. Hui, I. Zhang, E. Pappert, B. Navia (Tulsa, USA)

    Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…
  • MDS Virtual Congress 2021

    CSF MicroRNA Analysis Reveals Angiogenesis And Autophagy Defects In Parkinson’s DiseasePatients

    C. Moussa, Y. Torres-Yaghi, F. Pagan (Washington, USA)

    Objective: We investigated the effects of discoidin domain receptor (DDR)-1 inhibition on CSF miRNAs in Parkinson’s disease patients. Background: MicroRNAs (miRNAs) are post-transcriptional regulators of…
  • MDS Virtual Congress 2021

    Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results

    A. Lang, A. Siderowf, E. Macklin, W. Poewe, D. Brooks, H. Fernandez, O. Rascol, N. Giladi, F. Stocchi, C. Tanner, R. Postuma, D. Simon, E. Tolosa, B. Mollenhauer, M. Byrne, K. Fraser, J. Xiao, I. Sapir, J. Inra, R. Hutchison, M. Yang, T. Fox (Toronto, Canada)

    Objective: To evaluate cinpanemab (BIIB054) efficacy and safety. Background: Aggregated alpha-synuclein (α-syn), a major constituent of Lewy bodies, is thought to play a central role…
  • MDS Virtual Congress 2021

    Predictors of antidepressant and benzodiazepine treatment in Parkinson’s disease

    G. Gentile, G. Zanotelli, L. Weis, R. Biundo, F. Sambataro, A. Antonini (Padua, Italy)

    Objective: To assess the prevalence of antidepressant and benzodiazepine (BDZ) treatment in Parkinson’s disease (PD), to analyze treatment with respect to altered mood indication, and…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors

    A. Nicholas, C. Singer, I. Zhang, E. Pappert, B. Navia (Birmingham, USA)

    Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…
  • MDS Virtual Congress 2021

    A New Phase of the Parkinson’s Outcomes Project Registry Study

    A. Naito, C. Marras, J. Beck, R. Deleon, M. Neault, N. Dahodwala, T. Davis, M. Rafferty, A. Ramirez-Zamora, S. Luo (Miami, USA)

    Objective: Objective: To provide an update on the Parkinson’s Outcomes Project, a longitudinal study measuring outcomes among people with Parkinson’s disease (PwP). Background: Background: Data…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration

    W. Ondo, R. Hauser, A. Bowling, S. Isaacson, E. Pappert, B. Navia (Houston, USA)

    Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…
  • MDS Virtual Congress 2021

    A phase 2b randomized, double-blind, placebo-controlled study of suvecaltamide in the treatment of adults with moderate to severe essential tremor: study design and methodology

    A. Sterkel, W. Ondo, R. Elble, P. Lewitt, R. Pahwa, C. Urrea, L. Huang, L. Hickey, M. Baladi (Palo Alto, USA)

    Objective: Evaluate the efficacy and safety of JZP385 (formerly CX-8998), a highly selective T-type calcium channel modulator, for symptomatic control of moderate to severe essential…
  • MDS Virtual Congress 2021

    Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America

    R. Pahwa, S. Fox, J. Hui, C. Singer, J. Schwarz, M F. de Pandis, J. Raw, I. Zhang, E. Pappert, B. Navia (Kansas City, USA)

    Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 32
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Unusual prolonged survival in multiple system atrophy: A case report
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley